



FY2010 Business Results and Future Outlook

(May 10th, 2011)

Miraca Holdings Inc.

1



FY2010 Performance Overview

(Fiscal Year Ended March 31, 2011)

Please be aware of the following:

- * Figures and ratio in this material are rounded to the appropriate unit in principle.
- * The sums of the individual figures in each table do not always correspond to the total, because of rounding.

2




Summary of FY2010 Consolidated Performance (year-on-year comparison)

Net sales(+11.1%), Op. income(+7.7%) and Ordinary income(+7.0%) reached a record-high

- Significant sales growth due to acquisition of Care'x, JCL, and Innogenetics (INNX)
- Impact of weak sales of flu test kits was reduced by profitability improvement in each segment
- Decrease in net income due to extraordinary loss of 2.4 bn yen (loss on adjustment for changes of accounting standard for asset retirement obligations, business structure improvement expenses, etc.)

(billion yen)	FY2009	FY2010	Y/Y Variation
Net sales	149.1	165.7	16.6 (+11.1%)
In vitro diagnostics	32.9	35.8	2.9 (+8.8%)
Clinical lab testing	91.9	102.8	10.9 (+11.9%)
Healthcare related	24.3	27.1	2.8 (+11.5%)
Op. income	(*) 19.81 13.3%	(*) 21.33 12.9%	1.52 (+7.7%)
In vitro diagnostics	8.02 24.4%	7.82 21.8%	-0.20 (-2.5%)
Clinical lab testing	9.27 10.1%	10.85 10.6%	1.58 (+17.0%)
Healthcare related	2.50 10.3%	2.65 9.8%	0.15 (+6.0%)
Ordinary income	20.19 13.5%	21.60 13.0%	1.41 (+7.0%)
Net income	11.59 7.8%	11.17 6.7%	-0.42 (-3.6%)

(*) Elimination/corporate of 0.02 billion yen and 0.01 billion yen are included in Op. income for FY2009 and FY2010, respectively.



3

Summary of FY2010 Consolidated Performance (comparison to original forecast)

Net sales, Op. income and Ordinary income exceeded original forecast.

	Original forecast (May, 2010)	FY2010 Result	Variation
Net sales	161.7	165.7	4.0 (+2.5%)
In vitro diagnostics	32.3	35.8	3.5 (+10.8%)
Clinical lab testing	103.0	102.8	-0.2 (-0.2%)
Healthcare related	26.4	27.1	0.7 (+2.7%)
Op. income	20.20 12.5%	21.33 12.9%	1.13 (+5.6%)
In vitro diagnostics	7.15 22.1%	7.82 21.8%	0.67 (+9.4%)
Clinical lab testing	10.45 10.1%	10.85 10.6%	0.40 (+3.8%)
Healthcare related	2.60 9.8%	2.65 9.8%	0.05 (+1.9%)
Ordinary income	20.50 12.7%	21.60 13.0%	1.10 (+5.4%)
Net income	11.60 7.2%	11.17 6.7%	-0.43 (-3.7%)

● Impact of Tohoku Earthquake on FY2010 result:

- Net sales: - 0.3 bn yen

- Op. income: -0.2 bn yen


- Extraordinary loss: 0.06 bn yen

4


FY2010 Factors of Increase in Sales and Op. Income (year-on-year comparison)

Increase in both Net sales by 16.6 bn yen (+11.1%) and Op. income by 1.52 bn yen (+7.7%)

Consolidated Net Sales




Consolidated Op. Income



5

FY2010 Segment Performance Review (year-on-year comparison)

1. In Vitro Diagnostics




Increase in Net sales and Decrease in Op. income

◆ Net sales +2.9 bn yen

Consolidation of INNX (6-month sales): +3.6 bn yen

Organic growth

- Sales decline of flu test kits: -2.2 bn yen (Sales in FY2009 increased due to the pandemic of influenza)
 - Strong CL reagent sales: +0.5 bn yen
 - Sales increase from overseas business: +1 bn yen
- 0.7 bn yen**




◆ Op. income -0.2 bn yen

- Decrease in gross margin by sales decrease of flu test kits: -1.5 bn yen
- Increase in profit by increase in CL sales: +0.4 bn yen
- Increase in profit from overseas business: +0.6 bn yen
- Reduction in general expense: +0.2 bn yen

6

2. Clinical Lab Testing



Increase in both Net sales and Op. income

◆ Net sales +10.9 bn yen

Consolidation of JCL: +9.2 bn yen

Organic growth:

Off-site testing: +1.2 bn yen


- Price decline was at the same level as usual

- Increase in volume of testing due to sales promotion

+1.7 bn yen

FMS/Branch lab: +0.5 bn yen

- Steady sales growth at the existing clients



◆ Op. income +1.58 bn yen


- Increase in marginal profit due to sales growth: +1.1 bn yen

- Reduction in personnel expenses and general expenses: +0.2 bn yen


- Profitability improvement of JCL: +0.4 bn yen

(Amortization of goodwill on acquisition of JCL: -0.09 bn yen)

3. Healthcare Related



Increase in Net sales (+2.8 bn yen) and Op. income (+0.15 bn yen)



	Net sales	Op. income	(Factors)
Clinical Trials (CT)	-0.06 bn yen (-1.0%)	+0.08 bn yen (+10.8%)	• Decrease in sales due to delays in clinical trials • Streamlining pushed up Op. income
Sterilizing (ST)	+0.99 bn yen (+8.2%)	+0.23 bn yen (+25.6%)	• Growth in sales by obtaining new accounts • Op. income increased due to streamlining
Preventive Medicine Related (PM)	+1.92 bn yen (+30.4%)	-0.17 bn yen (-19.8%)	• Growth in nursing-care related and health checkup management segments • Slump in infection prevention products and food/environment analysis segments
Total	+2.8 bn yen	+0.15 bn yen	

FY2010

Consolidated Balance Sheet (billion yen)



Current assets 85.3	Current liabilities 31.8	→	Current assets 83.8	Current liabilities 32.5
	Long-term liabilities 9.9			Long-term liabilities 13.8
Fixed assets 51.8	Total net assets 95.4		Fixed assets 65.2	Total net assets 102.8
	[Treasury stock -0.5] Equity ratio: 69.4%			[Treasury stock -0.5] Equity ratio: 68.7%

Main factors of change

【Effect of M&A】

- Cash and cash equivalents: -11.7
- Property, plant, and equipment: +3.5
- Intangible fixed assets (excl. goodwill): +5.3
- Goodwill: +5.3
- Other assets: +6.5

→ Increase in total asset by 8.9 billion yen

【Net assets】 +7.4

- Net income +11.2
- Dividend paid -3.6

End of FY2009 (Mar.31, 2010)

Total assets: 137.1

ROE 12.7%
ROA 15.5%

End of FY2010 (Mar.31, 2011)

Total assets: 149.1 (+12.0 YoY)

ROE 11.3%
ROA 15.1%

FY2010 Consolidated Cash Flows (billion yen)



■ Consolidated Cash Flows

	FY2009	FY2010
Income before income taxes	19.3	19.3
Depreciation and amortization	9.0	10.0
Income taxes paid	-7.8	-8.7
Others	1.2	-0.3
Net cash provided by (used in) operating activities	21.8	20.4
Purchase of fixed assets	-5.2	-8.8
Purchase of subsidiaries	-2.2	-11.7
Others	0.7	-0.6
Net cash provided by (used in) investment activities	-6.6	-21.1
Free cash flows	15.1	-0.8
Net cash provided by (used in) financing activities	-3.0	-5.5
Effect of exchange rate change on cash and cash equivalents	-0.1	-0.2
Net increase/decrease in cash and cash equivalents	12.1	-6.4
Cash and cash equivalents at the end of financial period	39.5	33.1

【Effective use of cash for M&A activities】

(Year-on-year comparison)

● Net cash provided by operating activities: -1.4

- Income before income taxes was the same as FY2009
- Increase in depreciation and amortization: +1.0
- Income taxes paid: -0.9
(increased by net income increase for FY2009)
- Working capital and others: -1.5


● Net cash used in investment activities: -14.5

- Increase in expenses for purchase of subsidiaries: -9.5
(INN: -10.2, JCL: -1.5)
- Purchase of fixed assets: -3.6

● Net cash used in financing activities: -2.5

- Balance of payments for Interest-bearing liabilities: -1.9
- Increase in dividend paid: -0.4

* The amounts of capital expenditure have been changed from managerial accounting basis to financial accounting basis.



- FY2010 CAPEX increased mainly due to the investment in building and land for the new IVD factory in Obihiro, Hokkaido, of 1.4 bn yen (start operation in June, 2011), and Next-generation IT system (CLT business) of 0.6 bn yen. (※These two investments will be depreciated from FY2011)

Topics in FY2010 (1)

■ Acquisition of Innogenetics and future outlook

● Completion of acquisition in Sep. 2010

- The final goodwill increased to 4.42 billion yen (+0.16 billion yen)
(Adjustment of Net Working Capital and revision of acquisition cost)

● FY2010 results

Original forecast: Net sales 3.1 bn yen → Result: Net sales 3.6 bn yen
Op. income ±0% Ended in the black


● Future outlook

- FY2011 forecast: Net sales 6.7 bn yen
Profit generated by business restructuring will be used for advance investment for CL business expansion in Europe
- Phased headcount reduction from 1Q/FY2011 (Approx. 50 employees)
→ Reduction in personnel expenses of approx. 0.5 bn yen

● Business restructuring plan

- ① Reorganization as business base for promotion of CL products in Europe
- ② Global sales expansion of the company's products

Products: LiPA (Line Probe Assay)
LIA (Line Immunoassay)
Market: Asia, China, etc.
Sales supported by Fujirebio



■ Withdrawal from health promotion products business (November, 2010)

SRL launched health promotion products division as part of diversification plan in 1997.
(Planning of functional food and supply of its related materials)

● Reason for withdrawal: Sales decline (one-third of its peak) due to the rapid demand change in the health food market

⇒ FY2010 Sales: 0.8 bn yen ※Expenses for withdrawal was not posted.

■ Agreement of acquisition of Tsuchiya Enterprise (March, 2011)

SRL signed an agreement to acquire 100% shares of the company (Date of transfer of shares: May, 2011)

Tsuchiya Enterprise

- Founded in 1975
- Headquarters in Nagano prefecture
- Employees approx. 70 people
- Business domain: Clinical laboratory testing and other related business
- Sales: Approx. 0.9 bn yen (FY Dec. 2010)

● Purpose of acquisition:

Expansion of regional coverage in GP/Clinic market in Nagano area

⇒ Management shakeup, profitability improvement, and strengthening of its sales force

■ Merger of 4 subsidiaries into JCL (April, 2011)

● Purpose of consolidation: Strengthening of management bases through restructuring of sales structure

FY2011 Forecast

(Fiscal Year Ending March 31, 2012)

	FY2010	FY2011 Forecast	Variation
Net sales	165.7	174.0	8.3 (+5.0%)
In vitro diagnostics	35.8	41.2	5.4 (+15.1%)
Clinical lab testing	102.8	105.6	2.8 (+2.7%)
Healthcare related	27.1	27.2	0.1 (+0.4%)
Op. income	(*) 21.33 12.9%	22.00 12.6%	0.67 (+3.1%)
In vitro diagnostics	7.82 21.8%	7.90 19.2%	0.08 (+1.0%)
Clinical lab testing	10.85 10.6%	11.45 10.8%	0.60 (+5.5%)
Healthcare related	2.65 9.8%	2.65 9.7%	0.00 (±0.0%)
Ordinary income	21.60 13.0%	22.15 12.7%	0.55 (+2.5%)
Net income	11.17 6.7%	12.30 7.1%	1.13 (+10.1%)

(*) Elimination/corporate of 0.01 billion yen is included in Op. income for FY2010.

【Main factors of variation】


- Consolidation of INNX (full-year) contributes to sales increase in In Vitro Diagnostics
- Growth in off-site testing in existing business and non-organic growth in Clinical Lab Testing
- Healthcare Related maintains the same sales and profit level as FY2010

15

Forecast for 1Q and 1H of FY2011 Prospect of Profitability


- ① Consolidation of INNX → Increase in net sales for 1H/FY2011 by 3.1 bn yen (+4.0%)
 - ② Impact from Tohoku Earthquake → Decrease in net sales for FY2011 (mostly 1Q/FY2011) by 0.5~1.0 bn yen
 - ③ Strong performance in 1Q/FY2010 (temporary profitability increase at the NHI^(*) revision)
- ⇒ FY2011 Forecast: Profit decline is estimated in 1Q/FY2011. (* NHI: National Health Insurance)

Profitability will start improving in 2Q, and full-year Op. income will exceed FY2010.



16

1. In Vitro Diagnostics



Increase in Net sales (+5.4 bn yen) and Op. income (+0.08 bn yen)


◆ Net sales

Consolidation of INNIX (full-year): +3.1 bn yen

Existing business

- Growth in CL business in Japan: 1.7 bn yen
Promotion of installment of CL instruments, sales expansion of new reagent items, and increase in sales at JRC's relocation of testing sites (Increase in instruments sales)
- Sales increase at overseas business: +0.6 bn yen

+2.3 bn yen




◆ Op. income

- Profitability improvement at INNIX will be offset by investment for CL business expansion in Europe and amortization of goodwill
- Increase in profit of CL business in Japan and existing overseas business: +0.8 bn yen (Profit generated from instrument sales is small)
- Increase in R&D costs: -0.6 bn yen

Slight increase in profit

2. Clinical Lab Testing



Increase in Net sales (+2.8 bn yen) and Op. income (+0.6 bn yen)


◆ Net sales

● Off-site testing: +4.3 bn yen

- Price decline ratio is estimated to be normal
- Increase in new accounts and sales expansion of new test items
- Sales increase from M&A
- Sales for the government project, "Japan Eco & Child Study": +1.3 bn yen

● FMS/Branch lab: -1.5 bn yen

- Decrease of accounts (Trend of in-hospital, non-outsourcing testing is increasing due to the change of government reimbursement rate → Decrease in demand for FMS/Branch lab in some potential customers)




◆ Op. income

- Increase in marginal profit by increase in sales: +1.1 bn yen
- Expenses relating to earthquake countermeasure and electric power shortage: -0.4 bn yen
- Investment for decentralization of laboratories: -0.25 bn yen

FY2011 Forecast

(year-on-year comparison)


3. Healthcare Related



Increase in Net sales (+0.1 bn yen) and Op. income remains flat

Clinical Trials (CT):
Net sales +0.32 bn yen, Op. income +0.03 bn yen

- Clinical trial testing: Expansion of Multinational Clinical Trials
- CRO business: Advance investment for recruiting and training



Sterilizing (ST):
Net sales +0.38 bn yen, Op. income +0.07 bn yen

- Expansion of sales coverage
- Sales increase of operation-room related service and management of medical equipment

Preventive Medicine Related (PM)
Net sales -0.63 bn yen, Op. income -0.09 bn yen


- Nursing-care related: Expansion of sales area
- Health checkup management: Expansion of corporate customers
- Food/ environment analysis: Reorganizing of each business bases
- Withdrawal from health promotion products (FY2010 sales: 0.8 bn yen)

FY2011 Forecast


Consolidated R&D Expenses/Capital Expenditure (billion yen)




R&D expenses (R&D)



Capital expenditure (CAPEX)



Amortization and depreciation



Three companies by M&A (Care'x, JCL, and INNX)

- FY2011 R&D: Increased by development of IVD instruments and clinical development at overseas
- FY2011 CAPEX: Including on-going investment for Next-generation IT system (CLT business)
- * CAPEX of three companies will increase due to investment in production facility, construction for earthquake resistance, purchase of rental assets.
- FY2011 Amortization and depreciation will increase corresponding with FY2010 CAPEX.




FY2010 – FY2013

Medium-term Management Plan

- Current Status and Future Outlook -

The Status of FY2010-2013 Management Plan

FY2013 Target: Net sales 182.5 bn, Op. income 26.1 bn (yen)



【Business environment】

In Japan: Fierce competition, aging society with fewer children, damage from Tohoku Earthquake
 Overseas: Acceleration of consolidation of players and continuing market growth in emerging countries

【Achievement in FY2010】

Execution of M&A: impact on sales growth and business strategy
 → Significant growth in net sales
 → Increase in Op. income by streamlining in existing and acquired business

【Task to achieve FY2013 Target】

Expanding market share in Japan and driving globalization



Competitive strength and acceleration of M&A

FY2010-2013 Management Plan

FY2010 Achievement and Future Outlook

1. In Vitro Diagnostics – (1)

【Summary of FY2010 performance】

Progress of globalization through M&A activities

- Overseas sales ratio: **40%** (FY2011 forecast)
- Overseas employees: **Over 40%** (as of the end of FY2010)

(1) Europe: acquisition of INNX in Sep. 2010

- Acquisition of CL-business base (sales and R&D) in Europe
- IVD business function (presence) located in Europe
- Adding INNX's products into product portfolio

(2) Asia: launch of CL-business in Korea


- Started installment of CL instruments
- Reagent items: almost same as in Japan

(3) Transition to offshore production

(Reduction of foreign currency risk and of COGS)


- Feasibility study and preparation of offshore production at a subsidiary in Taiwan

◆ Overseas sales ratio



◆ Employees in IVD business

752 people (FY2005) → 1,237 people (FY2010)



FY2010-2013 Management Plan

FY2010 Achievement and Future Outlook

1. In Vitro Diagnostics – (2)

Launch of CL-business in Europe

- Business base: INNX (sales channel and clinical trial)
- Reagent items: 24 analytes (registration completed)
- Launch in Italy in FY2011 → Expand business area step by step
- FY2013 target of CL instrument installment: **50 units in Europe**

Establishment of key business base in the long term

Strengthening cost-competitiveness is necessary for expansion of global sales
 → Promotion of establishment of global production system

● The FY2013 target of CL instrument installment: **200 units in total (excl. Japan)**

Expansion of CL-business in Asia

- FY2013 target of CL instrument installment:
 - 80 units in Korea
 - 10 units in Taiwan
 - 60 units in China and other Asian countries

“Sales growth by geographical expansion” + “Cost reduction”
 → Business structure to survive in global competition

FY2010-2013 Management Plan

FY2010 Achievement and Future Outlook

2. Clinical Lab Testing – (1)

Focus on GP/Clinic market

- ① Acquisition of JCL
- ② Acquisition of Tsuchiya (to be completed in May, 2011)

Acquisition of business base for GP/Clinic market in western part of Japan (Kansai and Nagano area)


Future outlook

- ① Organic growth by strengthening of competitive edge
 - De-centralization of laboratories (Increase in quality of service)
 - Standardization (Cost competitiveness)
- ② Seek M&A opportunity driven by market consolidation

Driver of growth: new esoteric testing

- ① Development and expansion of new esoteric testing

◆ Sales of Companion Diagnostics for anticancer drug (billion yen)



- ② Undertaking of clinical testing for "Japan Eco & Child Study"

Future outlook


Development of new test items

Change in FMS/Branch-lab market

New category of reimbursement in hospital testing (from April, 2010)

Trend of in-hospital, non-outsourcing testing

◆ Sales of Off-site and FMS/Branch lab testing (billion yen)



* JCL is excluded from sales for FY2010.

Future outlook

Against wind of FMS/Branch-lab business


FY2010-2013 Management Plan

FY2010 Achievement and Future Outlook

2. Clinical Lab Testing – (2)

Change of regional lab function ("Decentralization" and "Standardization")

2010 2011 2012 2013 → 2015



◆ Clinical Trials

Stable growth by order increase

- Establishment of clinical testing system for Multinational Clinical Trials in Asia (seven countries)
 - ⇒ Increase to 15% of total sales in FY2013
- Close cooperation with laboratories/ R&D section
 - ⇒ Sales expansion of new testing items (e.g. biomarker)

◆ Sterilizing

Stable growth of sterilizing business and strengthening of related service segment


- Expansion of geographic area in sterilizing business
 - ⇒ Using regional business bases as foothold
- Expansion of related services
 - ⇒ Operation-room related service, management of medical equipment, logistics support, etc.

◆ Preventive Medicine Related


Expansion of nursing-care related and health checkup management

- Nursing-care related: Expansion of regional coverage and sales increase in current areas
- Healthcare checkup management: Obtaining new more corporate customers

◆ Sales ratio of Multinational Clinical Trials




◆ Coverage expansion in sterilizing business



Policy on Return to Shareholders


Increasing cash dividends based on stable dividend payout ratio, maintaining appropriate residual for investment for future growth.

◆ Cash dividends (yen per share) and payout ratio



Dividend increase with stable dividend payout ratio of over 30%

◆ Dividend on Equity Ratio (%)



Maintaining DOE of over 3%

(*) Source: Nomura Securities, Bloomberg data



Contact information:

IR Public Relations Group

Phone: +81-3-5909-3337

Email: ir@miraca-holdings.co.jp

URL: www.miraca-holdings.co.jp/eng/index.html

Disclaimer regarding forward-looking statement:

The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.